Efficacy and Pharmacogenomics of Salvage CLAG-M Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03150004|
Recruitment Status : Recruiting
First Posted : May 11, 2017
Last Update Posted : March 12, 2020
|Condition or disease||Intervention/treatment||Phase|
|Acute Myeloid Leukemia||Drug: Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen||Phase 2|
The optimal treatment regimen for relapsed/refractory acute myeloid leukemia (AML) is unknown. Although several chemotherapy options are available, there is no universally accepted regimen to date. One such regimen is CLAG-M (Cladribine, Cytarabine, Mitoxantrone, G-CSF) that has been frequently used at our center. However, it is difficult to predict which patients are likely to respond to CLAG-M or experience treatment-related toxicities. In patients with newly diagnosed AML, studies have demonstrated that achievement of minimal residual disease negative CR is associated with a better overall survival. However, this has not been clearly studied in patients with relapsed-refractory AML. Through this study, we aim to demonstrate the influence of achieving MRD negative CR on survival of patients with relapsed/refractory AML treated with CLAG-M. In addition to the conventionally used predictive factors, we aim to incorporate pharmacogenomics to assess the efficacy and toxicity of therapy.
To determine the complete remission (CR) rate and achievement of minimal residual disease (MRD) negativity after treatment with salvage CLAG-M chemotherapy regimen in patients with relapse/refractory and secondary AML.
- To determine the progression free survival (PFS) and overall survival (OS) of patients treated with CLAG-M chemotherapy regimen.
- To study the pharmacogenomics of patients receiving CLAG-M chemotherapy and determine its influence on survival, CR rate and MRD negativity.
- Determination of disease- or patient-related factors that predict MRD negativity and survival with CLAG-M.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||90 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Efficacy and Pharmacogenomics of Salvage CLAG-M Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia|
|Actual Study Start Date :||June 14, 2017|
|Estimated Primary Completion Date :||October 1, 2027|
|Estimated Study Completion Date :||October 1, 2029|
Experimental: CLAG-M regimen
Patients' treatment cycle is 30 days.
Drug: Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen
Patients will be started on CLAG-M regimen, which consists of the following:
- Minimal residual disease (MRD) complete remission (CR) rate [ Time Frame: Day 35 ]The number of participants who achieve MRD CR. Repeat bone marrow study will be obtained after the completion of CLAG-M therapy at day 30 or when absolute neutrophil count (ANC) recovers to >1000 cells/^3.
- Overall survival [ Time Frame: Year 4 ]The number of participants still alive following CLAG-M chemotherapy.
- Prediction of minimal residual disease (MRD) negativity [ Time Frame: Day 5 ]The number of participants predicted to have no minimal residual disease, using pharmacogenomics.
- Prediction of the development of treatment-related toxicities [ Time Frame: Day 5 ]The number of participants predicted to have treatment-related toxicities, using pharmacogenomics.
- Progression-free survival [ Time Frame: Year 4 ]The number of participants who don't experience progressive disease.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03150004
|Contact: Medical College of Wisconsin Clinical Cancer Centeremail@example.com|
|United States, Wisconsin|
|Froedtert & the Medical College of Wisconsin||Recruiting|
|Milwaukee, Wisconsin, United States, 53226|
|Contact: Ehab Atallah, MD 414-805-4600 firstname.lastname@example.org|
|Principal Investigator:||Ehab Atallah, MD||Medical College of Wisconsin|